Summit Therapeutics-Spon ADRSMMT
13F holders, Q3 2024 (September 30)2holders
0new positions
0sold out
$21.90avg. 13F price*
At the end of Q3 2024, 2 institutions reported holding Summit Therapeutics-Spon ADR (SMMT) in their 13F filings, unchanged from Q2 2024. 0 opened new positions and 0 sold out. The largest holders were Lindbrook Capital, LLC ($17K) and Rothschild Investment LLC ($3K).
- Company
- Summit Therapeutics-Spon ADR
- CUSIP
- 86627R102
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 75 shares bought and 56 shares sold, net +19 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Lindbrook Capital, LLC | 0.00% | Reduce -6.9% | 755 | $17K |
| Rothschild Investment LLC | 0.00% | Add +136.4% | 130 | $3K |
"% of holder's portfolio" is SMMT's weight in each manager's 13F, not the share of Summit Therapeutics-Spon ADR the manager owns.